Evidence map›Paper›PMID 41591580›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2026

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.

Yuanyuan Wang, Haoyue Guo, Ruoshuang Han, Yuhan Wu, Taiping He, Meng Diao, Anwen Xiong, Fei Zhou, Lei Cheng, Chao Zhao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuanyuan Wang *School of Medicine, Tongji University, Shanghai, 200092, China.
Haoyue Guo *School of Medicine, Tongji University, Shanghai, 200092, China.
Ruoshuang Han *Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Yuhan WuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Taiping HeSchool of Medicine, Tongji University, Shanghai, 200092, China.
Meng DiaoSchool of Medicine, Tongji University, Shanghai, 200092, China.
Anwen XiongSchool of Medicine, Tongji University, Shanghai, 200092, China.
Fei ZhouSchool of Medicine, Tongji University, Shanghai, 200092, China.
Lei ChengDepartment of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Chao ZhaoDepartment of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Xuefei LiDepartment of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Caicun ZhouSchool of Medicine, Tongji University, Shanghai, 200092, China. doctorcaicunzhou@163.com.

Funding

Shanghai Innovative Collaboration Project 2020CXJQ02
6 · The paper itself

Abstract

purposeEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used as the standard-of-care first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, EGFR-TKI resistance has become a major challenge for almost all patients with EGFR-mutated NSCLC. Both amivantamab (EGFR-MET bispecific antibody) and patritumab deruxtecan (HER3 antibody-drug conjugate) have shown promising efficacy in clinical trials for NSCLC resistant to osimertinib. This study aimed to evaluate a novel therapeutic strategy combining amivantamab and patritumab deruxtecan to overcome osimertinib resistance in NSCLC.

methodsThree osimertinib-resistant non-small cell lung cancer cell lines were established in vitro. Changes in relevant targets between pre- and post-resistance states were explored at the RNA and protein levels. Subsequently, the efficacy and safety of combination therapy were verified in vitro and in vivo respectively. Changes in treated mice immune microenvironment post-combination therapy were analyzed by flow cytometry, while bulk-RNA sequencing was conducted on tumor tissues.

resultsWe found that in vitro studies, when combined, amivantamab and patritumab deruxtecan both exhibited a synergistic effect on cell lines that were sensitive or resistant to Osimertinib, and the use of amivantamab increases the expression of HER3 in certain cell lines. Furthermore, the combination therapy polarized macrophages toward the M1 phenotype in vivo, thereby constructing an immune microenvironment unfavorable for tumor growth.

conclusionIn conclusion, we have proposed a new therapeutic strategy for NSCLC after osimertinib resistance. The combined strategy of amivantamab and patritumab deruxtecan highlight a promising therapeutic avenue, warranting future clinical trials to validate safety and efficacy.

Indexed as

AcrylamidesAniline CompoundsAntibodies, BispecificCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmImmunoconjugatesLung NeoplasmsProto-Oncogene Proteins c-metReceptor, ErbB-3AnimalsAntibodies, Monoclonal, HumanizedBroadly Neutralizing AntibodiesCell Line, TumorErbB ReceptorsFemaleHumansAcrylamidesamivantamabAniline CompoundsAntibodies, BispecificAntibodies, Monoclonal, HumanizedBroadly Neutralizing AntibodiesEGFR protein, humanErbB ReceptorsImmunoconjugatesIndolesosimertinibpatritumabProto-Oncogene Proteins c-metPyrimidinesReceptor, ErbB-3Antibody drug conjugateDrug resistanceEpidermal growth factor receptorHER3Non-small cell lung cancer

Identifiers

PMID41591580
PMCPMC12847129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.